Arabic Arabic English English French French German German
dark

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND

ediciNova, Inc. announced that an abstract regarding MediciNova’s ongoing Phase 2b/3 clinical trial of MN-166 in amyotrophic lateral sclerosis has been accepted for presentation at the 32nd International Symposium on ALS/MND to be held virtually on December 7 – 10, 2021. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

How Pharma Startups Can Remain Competitive in Today’s Market

Next Post

Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)

Related Posts
Total
0
Share